Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM

Launched by THE AFFILIATED HOSPITAL OF XUZHOU MEDICAL UNIVERSITY · Feb 5, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how certain genetic factors might affect how well a medication called exenatide works for people with Type 2 Diabetes Mellitus (T2DM). Exenatide is used to help control blood sugar levels, and the researchers want to see if variations in specific genes can predict how effective this treatment will be. They are looking for patients who have been diagnosed with T2DM, are between the ages of 25 and 70, and have a body mass index (BMI) between 20 and 35. Participants should also have specific blood sugar levels and must have had their health data collected both before and 6 months after starting the medication.

If you join this study, you will be part of a group that has been using exenatide for at least 12 months. The research team will analyze your genetic information alongside your treatment outcomes to better understand the relationship between genetics and medication effectiveness. It's important to know that individuals with certain serious health conditions or those who have recently taken specific medications may not qualify for this trial. Overall, this study aims to improve diabetes treatment by personalizing it based on genetic factors.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. a diagnosis of T2DM
• • 2. a body mass index (BMI) of 20-35 kg/m2
• • 3. an HbA1c of 7.0%-12%, an age of 25-70 years
• • 4. required data available at baseline and 6 months after GLP-1RA therapy.
• Exclusion Criteria:
• • 1. Patients with serious diseases such as acute myocardial infarction, cerebral vascular accident, trauma, kidney or liver diseases, severe gastrointestinal dysfunction, and history of pancreatitis
• • 2. patients receiving GLP-1 analogues, weight loss drugs, glucocorticoids, drugs affecting gastrointestinal peristalsis in the past 3 months
• • 3. those with missing data at the time points of baseline, 3 months, and 6 months after GLP-1 RA therapy.